Skip to main content
Apeloa Pharmaceutical Co.,Ltd. logo

Apeloa Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 000739 ISIN · CNE000000Q45 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,840 across all filing types
Latest filing 2026-03-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000739

About Apeloa Pharmaceutical Co.,Ltd.

https://www.apeloa.com

Apeloa Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and distribution of active pharmaceutical ingredients (APIs), intermediates, and finished dosage forms. The company operates three core business pillars: API production, Contract Development and Manufacturing Organization (CDMO) services, and finished drug products. Its therapeutic focus includes cardiovascular, anti-infective, anti-viral, and oncology treatments. Apeloa utilizes an integrated supply chain to deliver chemical and biological solutions to a global client base. The organization maintains compliance with international quality standards, including certifications from the FDA, EMA, and PMDA. Its CDMO services encompass the full product lifecycle, from process chemistry and analytical development to large-scale commercial manufacturing, supported by specialized technology platforms such as continuous flow chemistry and enzymatic synthesis.

Recent filings

Filing Released Lang Actions
关于对下属公司提供担保预计的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普洛药业股份有限公司 regarding the company's plan to provide guarantees for its subsidiaries' financing needs. It details the expected guarantee amounts, the financial status of the subsidiaries, and the board's opinion on the matter. The document is a formal disclosure about a financial arrangement (providing guarantees) and includes specifics about the guarantee limits, related parties, and risk assessment. It is not a full financial report, audit report, or earnings release. It is also not a notice of dividend, share issue, or management change. The document is a regulatory announcement about financing guarantees, which fits best under Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive financial data related to the guarantees, so it is not merely a report publication announcement or a regulatory filing fallback. Therefore, the classification is CAP with high confidence.
2026-03-19 Chinese
普洛药业股份有限公司对会计师事务所2025年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is titled as an evaluation report on the performance of the accounting firm for the 2025 annual audit of 普洛药业股份有限公司. It discusses the audit firm's independence, professional competence, audit scope, execution, and information security management related to the 2025 annual financial statements audit. The document does not contain the actual financial statements or detailed financial data but rather assesses the audit process and the auditor's performance. It is a standalone audit-related report focusing on the audit firm's duties and results, which fits the definition of an Audit Report / Information (AR). The document length is 1765 characters, which is short but contains substantive content about the audit evaluation, not merely an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2025
2026-03-19 Chinese
关于使用自有闲置资金进行理财投资的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 普洛药业股份有限公司 regarding the use of idle funds for financial investment. It details the investment amount, sources, risk analysis, and control measures, and mentions that the proposal will be submitted to the shareholders' meeting for approval. The document is short (1164 characters) and does not contain financial statements or detailed financial data. It is an announcement about a capital use plan and related shareholder authorization, not a financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP).
2026-03-19 Chinese
董事会议事规则
Governance Information Classification · 95% confidence The document is titled '董事会议事规则' which translates to 'Rules of Procedure for the Board of Directors' of 普洛药业股份有限公司. It details the structure, responsibilities, meeting procedures, voting rules, and record-keeping for the company's board of directors. There is no financial data, no report of financial results, no announcement of voting results, no management changes, no legal proceedings, no capital updates, and no other regulatory filings. The content is focused on governance practices and internal rules of the board. Therefore, this document fits the category of Governance Information (CGR). The document length is 6880 characters, which is substantive and not a mere announcement or certification. Hence, the classification is CGR with high confidence.
2026-03-19 Chinese
关于召开2025年年度股东会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2025 Annual General Meeting (AGM) of 普洛药业股份有限公司, including the meeting date, voting procedures, proposal list, and instructions for shareholders. It contains no actual financial statements or results but focuses on the meeting logistics, agenda, and voting details. This matches the description of AGM Information (AGM-R), which includes presentations and materials shared during the AGM. The document length is over 6000 characters and is not merely an announcement of a report publication, so it is not an RPA. Therefore, the correct classification is AGM Information (AGM-R).
2026-03-19 Chinese
2025年度利润分配和资本公积金转增股本方案
Notice of Dividend Amount Classification · 95% confidence The document is a temporary announcement from a listed company regarding its 2025 profit distribution and capital reserve to share capital conversion plan. It details the cash dividend distribution, share repurchase, and cancellation amounts, and includes audited net profit figures. The document is an announcement of the dividend and capital distribution plan, including specifics on cash dividends and share repurchases, but it is not a full annual report or financial statement. It is not a simple report publication announcement because it contains substantive financial data and detailed dividend scheme information. The document fits best into the category of Notice of Dividend Amount (DIV), as it announces dividend amounts, payment details, and related shareholder information.
2026-03-19 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.